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Abstract 
Background: Chemokines have been recognized as important modulators of angiogenesis, and they play critical 
roles in the development and metastasis of hepatocellular carcinoma (HCC), although their origins and latent molecu-
lar mechanisms remain elusive. The aim of this study was to investigate how activated hepatic stellate cells (a-HSCs) 
promote angiogenesis in HCC.
Methods: A total of 22 HCC patients were enrolled randomly. We used immunohistochemistry, western blotting, and 
enzyme-linked immunosorbent assay (ELISA) to analyse the production of interleukin-8 (IL-8) in a-HSCs derived from 
HCC tissues. The angiogenic effects of IL-8 in vitro and in vivo were assessed by ELISA, real-time quantitative polymer-
ase chain reaction, capillary tube formation assay, and chick embryo chorioallantoic membrane assay.
Results: The present study showed that IL-8 was enriched predominantly in the tumour stroma of HCC tissues and 
was mainly derived from a-HSCs, rather than from hepatoma cells, in vivo and in vitro. Angiogenesis was most active 
at the invading edge, which was close to the a-HSCs. The angiogenic effect was dramatically attenuated by an IL-8 
neutralizing antibody both in vitro and in vivo. Moreover, the IL-8 neutralizing antibody down-regulated Ser727-phos-
phorylated STAT3 levels in hepatoma cells treated with a-HSCs conditioned medium.
Conclusions: These findings reveal that a-HSCs within the stroma of HCC contribute to tumour angiogenesis via IL-8.
Keywords: Hepatocellular carcinoma, Activated hepatic stellate cells, Interleukin-8, Angiogenesis, Phospho-signal 
transducer and activator of transcription 3
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Background
Hepatocellular carcinoma (HCC) is one of the most com-
mon solid malignant neoplasms and a leading cause of 
cancer-related death worldwide [1, 2]. Tumour progres-
sion relies on interactions between tumour cells and 
their surrounding microenvironment [3, 4]. The tumour 
microenvironment consists of stromal components, 
growth factors, proteolytic enzymes, extracellular matrix 
(ECM) proteins, and inflammatory cytokines [5, 6]. These 
elements play critical roles in tumour cell proliferation 
and survival as well as in angiogenesis and metastasis.
Angiogenesis plays a pivotal role in tumour growth and 
metastasis [7–9]. Dense tumour vasculature is associ-
ated with poor prognosis in certain types of cancer [10, 
11]. Angiogenesis is regulated by transcription factors 
such as hypoxia inducible factor-1 (HIF-1), nuclear fac-
tor κB (NF-κB), and signal transducer and activator of 
transcription 3 (STAT3) [12]. In HCC, a net excess of 
angiogenic factors, including vascular endothelial growth 
factor (VEGF)-A, angiopoietins (Angs), and platelet-
derived growth factor (PDGF)-B, is produced by tumour 
cells, vascular endothelial cells, immune cells, and peri-
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The tumour microenvironment is composed of vari-
ous cell types that influence the angiogenic response. 
Hepatic stellate cells (HSCs), the main type of stromal 
cell in the liver, are activated by tumour cells, inflam-
matory cytokines, and tumour-derived factors that are 
present in the surrounding milieu [15, 16]. Studies have 
suggested that activated HSCs (a-HSCs) play a crucial 
role in tumour angiogenesis and tumourigenesis [14, 
17]. A-HSCs can promote the invasion of HCC cells by 
secreting matrix metalloproteinases (MMPs), urokinase-
type plasminogen activator (uPA), interleukin-8 (IL-8), 
cyclooxygenase-2 (COX-2), and other factors [18–21].
IL-8, alternatively known as CXC motif ligand 8 
(CXCL-8), is a proinflammatory CXC chemokine [22–
24]. Its biological effects are mediated through binding to 
two cell surface G protein-coupled receptors, CXC motif 
receptor 1 (CXCR1) and CXCR2 [12, 25, 26]. Accumu-
lating evidence has demonstrated that IL-8 is associated 
with tumour angiogenesis, metastasis, and poor progno-
sis in many types of cancer [27–30]. However, the precise 
mechanism by which IL-8 promotes tumour angiogen-
esis in HCC is not fully understood.
In this paper, we demonstrated that a-HSCs played 
an important role in angiogenesis associated with 
HCC. A-HSCs secreted IL-8, which in turn stimulated 
hepatoma cells (Hep3B and Huh-7) to express angiogenic 
factors, such as VEGF-A, to promote angiogenesis. Fur-
thermore, we showed that a-HSCs promoted angiogen-
esis via IL-8 by up-regulating Ser727-phosphorylated 
STAT3 levels in hepatoma cells. These findings charac-
terized certain interactions within the tumour microen-
vironment, and the data may help researchers develop 
more effective therapeutic strategies against HCC.
Methods
Patients and specimens
Pathologically confirmed HCC samples were obtained 
from 22 patients undergoing hepatectomy between 2013 
and 2014 at the Department of Hepatobiliary Surgery of 
the Third Affiliated Hospital of Sun Yat-sen University 
in Guangzhou. These patients provided signed informed 
consent, and they had received no previous local or sys-
temic treatment before the operation. Individuals with 
autoimmune disease, HIV or syphilis were excluded. 
The clinical stage was classified according to the guide-
lines of the International Union against Cancer. The clini-
cal characteristics of all the patients are summarized in 
Additional file 1: Table S1. All the samples were anony-
mously coded in accordance with the local ethical guide-
lines (as stipulated by the Declaration of Helsinki). The 
experiments were conducted in strict accordance with 
a study design approved by the Clinical Research Ethics 
Committee at the Third Affiliated Hospital of Sun Yat-sen 
University in Guangzhou.
Cell lines
Human hepatoma cell lines (Hep3B and Huh-7) were 
purchased from the Chinese Academy of Sciences. Pri-
mary HSCs were separated from the fresh tissue as 
described previously [31]. To minimize culture stress 
and clonal selection, HSCs passaged for up to 4-10 dou-
blings were used for the experiments. Human umbilical 
vein endothelial cells (HUVECs) were isolated from fresh 
human umbilical cords with collagenase I (1  mg/mL; 
Sigma, USA) [32]. Only primary HUVECs at passages 3-6 
were used in this study to avoid age-dependent cellular 
modifications [33].
Capillary tube formation assay
Diluted Matrigel (Matrigel: Medium 199 = 1:2) (BD, Bio-
science, USA) was added to a 96-well plate (50 mL/well) 
and allowed to polymerize for 2 h at 37 °C. HUVECs were 
then added at a density of 3 ×  104 cells per well in the 
96-well plate with serum-free conditioned media from 
hepatoma cells, which were treated or not with HSC 
serum-free culture supernatant with or without the IL-8 
neutralizing antibody (R&D Systems, USA) for 8  h in a 
5  % CO2 incubator at 37  °C. Bloodvessel branch points 
were visualized by phase microscopy and quantitated in 3 
random fields per well (10×) [34].
Immunohistochemical staining
Paraffin-embedded and formalin-fixed samples were cut 
into 4-µm-thick sections, which were then processed for 
immunohistochemical staining as previously described 
[35].
Immunofluorescence assay
A-HSCs growing in the 24-well flat-bottom plates were 
fixed, and stained with rabbit-anti-human monoclonal 
antibodies against alpha smooth muscle actin (α-SMA), 
vimentin and immunoglobulin (IgG, control) (Abcam, 
Cambridge, MA, USA) followed by treatment of AF488-
conjugated donkey-anti-rabbit IgG (Molecular Probes, 
Carlsbad, CA, USA). The cell nuclei were counterstained 
with 4′-6-diamidino-2-phenylindole (Sigma-Aldrich, St. 
Louis, MO, USA) as previously described [36, 37]. These 
images were assessed using a fluorescence microscope 
(Leica DMI 4000B, Germany) at a wavelength of 488 nm 
and analysed with Leica Application suite software (ver-
sion 4.0).
Enzyme‑linked immunosorbent assay (ELISA)
Concentrations of IL-8 and VEGF-A were detected by 
ELISA (R&D Systems, USA) as previously described [38]
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Chick embryo chorioallantoic membrane (CAM) assay
White leghorn chicken eggs on the fifth day after ferti-
lization were purchased from the Animal Husbandry 
Institute of South China Agricultural University. The air 
chambers of these eggs were windowed after disinfec-
tion with 75 % alcohol. The shell membranes were then 
removed carefully, and a 50 μL droplet was pipetted onto 
the CAM. These windows were sealed with sterile venti-
late surgical tapes, and the eggs were incubated without 
rotation at 80  % relative humidity and at 37.8  °C in the 
incubator. After 48 h, the results were observed under a 
ZEISS Lumar.V12 stereomicroscope.
Multiplex bead–based enzyme–linked immunosorbent 
assay
According to the manufacturer’s instructions and a pre-
viously described method [39], conditioned supernatants 
were analysed using the multiplex bead–based Enzyme–
Linked Immunosorbent Assay system (Millipore, Bill-
erica, MA, USA). The results were analysed using a 
Luminex plate reader and the Milliplex analyst software 
(Luminex 200 System).
Western blotting
For western blotting, proteins were separated by 10 
or 15  % SDS-acrylamide gels and then transferred to 
0.20  μM nitrocellulose membranes. After immunoblot-
ting with an antibody against glyceraldehyde-phosphate 
dehydrogenase (GAPDH; Santa Cruz Biotechnology, 
USA), the protein expression of IL-8 and other markers 
was detected with an ECL kit. The antibodies included 
the following: NF-κB p65 (C22B4; #4764) and STAT3 
(124H6; #9139), as well as their phosphorylated forms 
(Ser536-phosphorylated NF-κB p65: 93H1, #3033; 
Ser727-phosphorylated STAT3: #9134) (Cell Signaling, 
Beverly, MA, USA); HIF-1α (Cell Signaling, Beverly, MA, 
USA); and GAPDH and β-actin (Santa Cruz Biotechnol-
ogy, USA).
Real‑time quantitative polymerase chain reaction (qPCR) 
analysis
Total RNA was extracted from cultured hepatoma cells 
using the TriPure Isolation Reagent (Roche Applied Sci-
ence, Germany). The qPCR analysis of mRNA was exe-
cuted according to the manufacturer’s instructions. The 
qPCR primer sequences corresponding to angiogenic 
factors are described in Table  1. All the reactions  were 
performed in triplicate.
Statistical analysis
The data are presented as the mean  ±  standard error 
of the mean (SEM). The differences between groups 
were analysed using Student’s t test if only two groups 
were compared or using one-way analysis of variance 
(ANOVA) if more than two groups were compared. All 
the statistical tests were two-sided. All the experiments 
were performed at least three independent times. P val-
ues < 0.05 were considered statistically significant.
Results
A‑HSCs secreted high levels of the inflammatory 
chemokine IL‑8
To confirm that a-HSCs facilitate tumour angiogenesis, 
we first isolated a-HSCs from HCC tissues. A-HSCs were 
identified based on the high expression of the fibroblast-
specific markers α-SMA and vimentin using fluorescence 
microscopy (Fig.  1A). Using the Multiplex bead-based 
Enzyme–Linked Immunosorbent Assay system, the lev-
els of various inflammatory chemokines that are closely 
associated with angiogenesis, including GRO (α, β, and 
γ), CXCL-5, CXCL-6, CXCL-7 and IL-8, were detected 
in the 50  % a-HSC conditioned medium (HSC-CM) 
(CM:HSC-CM = 1:1) [23]. A-HSCs secreted significantly 
higher levels of IL-8 than of any other inflammatory 
chemokines (Fig. 1B).
It was reported that tumour cells also secret the angio-
genic factor IL-8 [12]. Therefore, we compared the lev-
els of IL-8 secreted by a-HSCs with those secreted by 
hepatoma cells. The ELISA assay revealed that the con-
centration of IL-8 in the a-HSC culture medium was 
markedly higher than that in the culture medium of 
Table 1 Primer sequences for angiogenic factors
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hepatoma cells (Fig.  1C). Consistently, IL-8 production 
by a-HSCs and hepatoma cells was further confirmed by 
Western blotting (Fig. 1D).
IL‑8 was mainly enriched in the HCC stroma in vivo
To further study the role of IL-8 in tumour angiogen-
esis, we detected the distribution of IL-8 in tumour tis-
sues from patients with HCC by immunohistochemistry. 
As shown in Fig. 1E (a and b), IL-8 was mainly enriched 
in the stroma surrounding the tumour, where numer-
ous a-HSCs, as detected based on the fibroblast-specific 
marker α-SMA, were also present. This finding further 
confirmed that a-HSCs were the main source of IL-8 
in HCC tissues. Furthermore, immunohistochemical 
staining for CD31 (Abcam, Cambridge, MA, USA), a 
microvessel marker, revealed that neovascularization 
occurred largely at the invading tumour edge, and close 
to the tumour stroma (Fig. 1E (c)).
IL‑8 neutralizing antibody suppresses tumour 
angiogenesis in vitro and in vivo
To study the effect of IL-8 secreted by a-HSCs on angio-
genesis, we collected the supernatants of a-HSCs and 
hepatoma cells cultured in the 50 % serum-free medium. 
Fig. 1 A-HSCs expressed high levels of IL-8. A Immunofluorescent staining of primary human a-HSCs isolated from a representative sample of 
HCC with an anti-α-SMA antibody,anti-vimentin antibody, and IgG. Scale bar, 50 μM. B The levels of various angiogenic chemokines in the cell-free 
culture supernatants of the a-HSCs were measured by Multiplex bead–based enzyme–linked immunosorbent assay at day 2. The data are expressed 
as mean ± SEM of triplicates. (C) The concentrations of IL-8 (pg/mL) in the supernatants of a-HSCs and hepatoma cells were determined by ELISA. 
The concentration of IL-8 in the a-HSCs culture medium was markedly higher compared with hepatoma cells. (D) The expression of IL-8 in the 
abovementioned cells was assessed by Western blotting. A-HSCs spontaneously released large amounts of IL-8, whereas hepatoma cells produced 
low levels of IL-8. (E) Hepatocarcinoma samples were stained with various antibodies, and different levels of antibodies expression can be seen on 
the same section. E (a) Immunohistochemical staining for α-SMA (1:1000) to identify a-HSCs in the tumour stromal region. E (b) The IL-8 distribution 
in hepatocarcinoma samples was visualized by immunohistochemical staining using the IL-8 neutralizing antibody (1:400). E (c) Neovascularization 
in hepatocarcinoma samples was visualized by immunohistochemical staining for CD31 (1:400). Scale bar 200 μM. One of the 22 representative 
micrographs is shown
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Supernatants from untreated hepatoma cells afterculture 
for 24 h had only a slight effect on HUVEC tube forma-
tion. Supernatants from hepatoma cells that had been 
exposed to HSC-CM for 24  h significantly promoted 
angiogenic tube formation (Fig. 2a, b). Furthermore, the 
number of branch points within the capillary-like struc-
tures was dramatically reduced by the IL-8 neutralizing 
antibody (Fig. 2d, e).
A similar effect of a-HSCs and IL-8 on tumour angio-
genesis was also observed in the CAM animal model 
(Fig. 2c). The group of eggs that was treated with HSC-
CM showed more marked signs of angiogenesis com-
pared to the other two groups in the CAM assay. 
Consistently, treatment with the IL-8 neutralizing anti-
body markedly inhibited angiogenesis.
IL‑8 neutralizing antibody down‑regulated the expression 
of angiogenic factors in HSC‑CM‑treated hepatoma cells
We next investigated the secretion of angiogenic fac-
tors in hepatoma cells under various conditions. 
VEGF-A levels were higher in the medium from HSC-
CM-treated hepatoma cells (Hep3B and Huh-7) than 
from normal medium-treated hepatoma cells (Hep3B: 
p = 0.0193; Huh-7: p = 0.0155). Notably, the concentra-
tion of VEGF-A was dramatically decreased when the 
HSC-CM-treated hepatoma cells were treated with the 
IL-8 neutralizing antibody (Hep3B: p  =  0.0152; Huh-
7: p =  0.0065) (Fig.  3). Consistent with the above find-
ings, HSC-CM up-regulated the levels of VEGF-A 
mRNA (p =  0.010) and VEGF-B mRNA (p =  0.034) in 
Hep3B cells compared to the normal medium (Fig.  4). 
Fig. 2 IL-8 neutralizing antibody repressed tumour angiogenesis in vitro and in vivo. a, b Soluble factors derived from HSC-CM-treated hepatoma 
cells induced angiogenic tube formation in vitro. The tube formation assay was done using HUVECs in the presence of serum-free conditioned 
medium from hepatoma cells, HSC-CM-treated hepatoma cells alone or supplemented with an IL-8 neutralizing antibody, and the IL-8 neutralizing 
antibody dramatically inhibited HUVEC tube formation. The illustrated results represent six separate experiments. c In the CAM assay, more capillary-
like structures developed in the presence of serum-free supernatants from Hep3B cells exposed to the 50 % serum-free HSC-CM compared with 
supernatants from untreated Hep3B cells. The number of these capillary-like structures was significantly reduced by the IL-8 neutralizing antibody. 
d, e Representative images of the number of branch points generated by HUVECs in vitro. The data are presented as mean ± SEM of four independ-
ent experiments. *p < 0.05; **p < 0.01
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Additionally, the IL-8 neutralizing antibody effectively 
down-regulated VEGF-A mRNA (p = 0.034) and VEGF-
B mRNA (p = 0.048) levels. However, the mRNA levels 
of other angiogenic factors (PDGF-A, PDGF-B, PDGF-C 
and Angiopoietin-1 (Ang-1)) did not change significantly. 
In Huh-7 cells, the mRNA expression of angiogenic fac-
tors (VEGF-A (p = 0.008), VEGF-B (p = 0.031), PDGF-B 
(p = 0.007), and PDGF-C (p = 0.047)) was up-regulated 
in response to stimulation with HSC-CM. The mRNA 
levels of these angiogenic factors (VEGF-A (p =  0.005), 
VEGF-B (p = 0.0244), PDGF-B (p = 0.001), and PDGF-C 
(p = 0.022)) were significantly reduced by the IL-8 neu-
tralizing antibody. Nevertheless, PDGF-A mRNA and 
Ang-1 mRNA levels remained unchanged in response to 
various conditioned media.
IL‑8 neutralizing antibody down‑regulated 
Ser727‑phosphorylated STAT3 levels in HSC‑CM‑treated 
hepatoma cells
Evidence suggests that IL-8 modulates tumour angio-
genesis by up-regulating the expression of the HIF-1, 
NF-κB, and STAT3 transcription factors [12]. We used 
western blotting to analyse these signalling pathways in 
hepatoma cells exposed to HSC-CM (Fig.  5a). Amongst 
these pathways, only Ser727-phosphorylated STAT3 was 
activated in HSC-CM-treated hepatoma cells (Fig. 5b, c). 
Moreover, Ser727-phosphorylated STAT3 was effectively 
inhibited in HSC-CM-treated hepatoma cells by the IL-8 
neutralizing antibody, whereas HIF-1α and NF-κB p65 
activation was not affected (Fig.  5d–f). Taken together, 
these results demonstrated that a-HSCs partially exerted 
their angiogenic function via IL-8, which up-regulated 
Ser727-phosphorylated STAT3 levels in hepatoma cells.
Discussion
Although a series of studies has indicated that a-HSCs 
play a key role in tumour angiogenesis, recurrence, 
and metastasis [31, 40, 41], the underlying mechanism 
remains incompletely understood. Our study demon-
strated that a-HSCs produce a large amount of IL-8 
in vitro; IL-8 was enriched predominantly in the tumour 
stroma rather than in the cancer nests of HCC samples. 
Furthermore, the IL-8 neutralizing antibody partially 
attenuated the ability of HSC-CM to induce angiogenesis 
and down-regulated Ser727-phosphorylated STAT3 lev-
els in hepatoma cells. These findings revealed a distinct 
interaction between a-HSCs and hepatoma cells within 
the tumour microenvironment, which promoted tumour 
angiogenesis.
It is generally believed that the tumour stroma plays 
a key role in angiogenesis associated with HCC, and 
that a-HSCs are enriched predominantly in the tumour 
stroma [5, 18, 42]. However, the specific contributions of 
these a-HSCs to HCC angiogenesis have not been exten-
sively studied. The present study provides evidence that 
a-HSC-derived IL-8 promoted angiogenesis in HCC. 
Several of our observations support this notion. First, 
a-HSCs were present primarily in the tumour stroma. 
Second, neovascularization was more active at the invad-
ing tumour edge, which is closer to the tumour stroma. 
Third, IL-8 was secreted in  vitro mainly by a-HSCs, 
rather than by hepatoma cells. Finally, IL-8 was enriched 
predominantly in the tumour stroma, and the main dis-
tribution area of IL-8 corresponded with the location of 
a-HSCs in vivo.
IL-8 is a potent pro-inflammatory cytokine that plays 
a critical role in tumour angiogenesis, a crucial step in 
tumour progression [30, 43]. When CD1 nude mice 
bearing DLD-1HIF−kd xenografts were treated with the 
IL-8 neutralizing antibody, the vessels were dramati-
cally narrowed and fragmented, and the vascular density 
decreased [44]. In the current study, we observed that 
culture supernatants from HSC-CM-treated hepatoma 
cells significantly promoted angiogenic tube formation, 
and the angiogenic effects were significantly reduced by 
the IL-8 neutralizing antibody in vitro and in vivo. These 
results indicated that a-HSC-derived IL-8 is essential for 
HCC angiogenesis.
Previous studies have confirmed that IL-8 receptors 
(CXCR1 and CXCR2) are expressed on the surface of 
hepatoma cells [30]. IL-8 functions via its high-affinity 
receptors, CXCR1 and CXCR2 [26]. Evidence has indi-
cated that IL-8 is closely associated with angiogenic 
Fig. 3 VEGF-A levels in the supernatant of hepatoma cells subjected 
to various treatments. The concentrations of VEGF-A (pg/mL) were 
assessed in the presence of serum-free conditioned medium from 
hepatoma cells, HSC-CM-treated hepatoma cells alone or sup-
plemented with an IL-8 neutralizing antibody by ELISA. The IL-8 
neutralizing antibody significantly down-regulated VEGF-A levels in 
the supernatant of hepatoma cells that were treated with 50 % HSC-
CM for 24 h. The data are expressed as mean ± SEM of triplicates. 
*p < 0.05; **p < 0.01
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factors during tumourigenesis [12, 45]. As a key mediator, 
IL-8 stimulates VEGF expression by activating the NF-κB 
pathway in endothelial cells [46]. Tumour angiogenesis 
is modulated by IL-8 via the up-regulated expression of 
the HIF-1, NF-κB, and STAT3 transcription factors [12]. 
However, in HIF-1-deficient tumours, IL-8 neutralization 
Fig. 4 IL-8 neutralizing antibody down-regulated the mRNA expression of angiogenic factors in HSC-CM-treated hepatoma cells. a–f mRNA 
expression of angiogenic factors (VEGF-A, VEGF-B, PDGF-A, PDGF-B, PDGF-C, and Ang-1) in hepatoma cells after various treatments. In Hep3B cells, 
the mRNA levels of VEGF-A and VEGF-B were up-regulated in response to stimulation with HSC-CM and were down-regulated by IL-8 neutralizing 
antibody. The mRNA levels of PDGF-A, PDGF-B, PDGF-C, and Ang-1 remained unchanged in response to various conditioned media. In Huh-7 cells, 
the mRNA levels of VEGF-A, VEGF-B, PDGF-B, and PDGF-C were up-regulated in response to stimulation with HSC-CM and were down-regulated 
by IL-8 neutralizing antibody. The mRNA levels of PDGF-A and Ang-1 remained unchanged in response to various conditioned media. The data are 
presented as mean ± SEM of three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001
Page 8 of 10Zhu et al. J Transl Med  (2015) 13:365 
evokes a marked inhibition of tumour growth and angi-
ogenesis [44]. In the current study, we found that IL-8 
up-regulated angiogenic factors in hepatoma cells. Sur-
prisingly, this process did not involve the transcrip-
tion factor HIF-1α, NF-κB p65, Ser536-phosphorylated 
NF-κB p65, or STAT3, but instead required the activation 
of Ser727-phosphorylated STAT3. Our results provide 
direct evidence supporting the critical role of a-HSCs 
in HCC progression and reveal a fine-tuned collabora-
tion between stromal cells and cancer cells in the tumour 
milieu.
The current understanding of the effect of a-HSCs 
on tumour angiogenesis strongly supports our findings 
[19, 40, 47]. Our research has some limitations. First, 
the 22 tumour samples evaluated in our study were not 
representative of all types of HCC, and the cohort was 
small considering the different conditions of these HCC 
patients. Second, further studies are needed to elucidate 
the molecular mechanism by which a-HSCs promote 
angiogenesis. Despite these shortcomings, our analysis 
shows that a-HSC-derived IL-8 plays a pivotal role in 
HCC-associated angiogenesis and reveals a fine-tuned 
collaboration between stromal cells and cancer cells in 
the tumour milieu. Larger studies are necessary to fully 
address this important question.
Conclusions
Our results indicate that a-HSCs promote HCC angio-
genesis via IL-8, which provides important new insights 
into the roles of a-HSCs in HCC progression. Under-
standing the mechanisms of a-HSC-mediated angiogen-
esis in HCC will aid in the rational design of promising 
targets for anti-tumour therapy.
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